Daratumumab for inherited cavernous malformations safety study
Treatments studied
Part of Blood & lymphatic, Brain & nervous system, Cancer, Genetic & congenital, Heart & circulation clinical trials.
This trial tests if daratumumab can help people with inherited cavernous malformations (clusters of abnormal blood vessels in the brain) who have had symptoms like bleeding or seizures. It aims to see if the drug is safe and might reduce future problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have a type of cavernous malformation that runs in families (more than one spot or a family history)
- You have had symptoms like bleeding, strokes, seizures, or other brain-related issues
- A doctor has said surgery is not a good option for you
- You are willing to attend regular clinic visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how to best treat people with untreated cerebral cavernous malformations (a cluster of abnormal blood vessels in the brain). It compares outcomes between those who have surgery and those who are monitored with regular check-ups, and will follow participants for a long time to see how they do.
This trial tests if daratumumab, a targeted antibody therapy, can help patients with aplastic anemia that hasn't improved after standard treatments. It's for adults who cannot or choose not to have a stem cell transplant.
This study follows people with a hereditary form of cavernous malformations (clusters of abnormal blood vessels in the brain). It aims to understand how the condition changes over time, without testing any new treatments.
This trial tests if daratumumab can help people with a kidney condition called MGRS, where abnormal proteins damage the kidneys. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
This trial tests if sirolimus, a medicine that may help reduce abnormal blood vessels, can prevent another brain bleed in people who recently had a bleed from a brainstem cavernoma. You would receive either sirolimus or a placebo to see if it works.
This trial tests a combination of three drugs (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) for people with rare kidney diseases caused by abnormal plasma cells. It aims to see if this treatment can help control the disease and protect kidney function.
Hear when a new Cavernous Malformation, Cerebral trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.